Engineered Anti-MAGE-A T-Cells Show Early Promise

Article

Genetically engineered T-cells targeting a common tumor antigen appeared safe and demonstrated some evidence of antitumor activity in a first-in-human clinical evaluation.

Marcus Butler, MD

Genetically engineered T-cells targeting a common tumor antigen appeared safe and demonstrated some evidence of antitumor activity in a first-in-human clinical evaluation.

The first 6 patients treated with either of 2 doses of engineered T-cells targeting melanoma-associated antigen-A4 (MAGE-A4) had a variety of adverse events (AEs), but treatment-related grade ≥3 AEs occurred in a minority of the patients. Four of the 6 heavily pretreated patients had stable disease as best response, including 1 who had ongoing stable disease at 6 weeks, as reported in a poster presentation at the European Society for Medical Oncology Annual Congress in Munich, Germany.

“MAGE-A4 SPEAR (specific peptide enhanced affinity receptor) T-cells at the 0.1 x 109 and 1.0 x 109 transduced doses appear to show no evidence of alloreactivity or off-target toxicity,” Marcus Butler, MD, of Princess Margaret Cancer Center in Toronto, and colleagues concluded. “The most frequent adverse events and treatment-related adverse events are consistent with those typically experienced by cancer patients undergoing cytotoxic chemotherapy or other cancer immunotherapies.”

“Transduced T-cells are detectable in the peripheral blood and expand transiently at lower doses and exhibit greater peak and duration of persistence at a higher T-cell dose…Preliminary data support continued investigation of MAGE-A4 SPEAR T-cells in the study populations.”

A broad variety of solid tumors express MAGE-A4. Genetically engineered SPEAR T-cells directed against a MAGE-A4 peptide (MAGE-A4c1032 T-cells) expressed on tumors, in the context of human leukocyte antigen (HLA)-A*02 have been developed for evaluation in patients with various advanced solid tumors. Butler and colleagues reported findings from the ongoing initial dose-finding clinical evaluation of the engineered T-cells.

Patients eligible for the trial are HLA-A*02+ (excluding *02:05 and *02:07 or null as sole *02 allele). Qualifying cancers consist of MAGE-A4+ inoperable or metastatic non—small cell lung cancer, urothelial cancer, melanoma, synovial sarcoma, myxoid/round cell liposarcoma, squamous cell head and neck cancer, ovarian cancer, gastric cancer, or esophageal cancer.

Groups of 3 to 6 patients receive MAGE-A4c1032 T-cells at doses of 0.1 to 5 x 109 cells, following fludarabine-cyclophosphamide condition. The trial will proceed to an expansion phase to a total of 30 patients, with the remaining patients treated at the highest tolerated dose.

The first 6 patients treated with the engineered T-cells all had stage IIIc-IVa ovarian cancer. Their ages ranged from 39 to 78, and they had received multiple prior therapies.

All 6 patients had grade ≥3 lymphopenia and neutropenia, but only 1 case each was considered treatment-related. Five patients had decreased appetite, fatigue, and nausea, none of which reached grade ≥3 severity. Four patients each developed anemia (all grade ≥3), dyspnea (no grade ≥3), and leukopenia (all grade ≥3). Febrile neutropenia occurred in 3 patients (all grade ≥3), and 3 patients developed thrombocytopenia (grade ≥3 in 2 of 3 cases). No patient had a dose-limiting toxicity as determined by investigator and Safety Review Committee assessment.

Four patients had a total of 8 serious AEs, consisting of 1 case each of pancytopenia, atrial fibrillation, cytokine release syndrome (treatment-related), hyponatremia, muscular weakness (treatment-related), encephalopathy (treatment-related) syncope, and pleural effusion.

Laboratory analyses of patients treated at the first 2 dose levels showed persistence of the engineered T-cells in peripheral blood for as long as 100 days. Follow-up continued in some cases.

Enrollment continues at the third dose level of the engineered T-cells (5 x 109 cell dose).

Hong D, Butler M, Johnson M, et al. Initial Safety Assessment of MAGE-A4 Specific Peptide Enhanced Affinity Receptor (SPEAR) T-Cells. Presented at the 2018 ESMO Congress; October 19-23, 2018; Munich, Germany. Abstract 1156P.

<<< 2018 ESMO Congress

Related Videos
In this third episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss the potential benefits of utilizing immunotherapy approaches earlier on in the disease course.
A panel of 5 experts on renal cell carcinoma
A panel of 5 experts on renal cell carcinoma
In this second episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, explain the challenges faced with preventing or detecting these cancers early and the understanding that is needed to develop effective early detection methods and move the needle forward.
In this first episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss the potential for early detection multiomic assays and the work that still needs to be done to encourage their widespread use.
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Wenxin (Vincent) Xu, MD,
Gottfried Konecny, MD